Biochemical Engineering Special Interest Group
biological engineering professionals
16 February 2016

SoCal and UK-Based Startup Akarna Therapeutics Gets $15 Million

Akarna Therapeutics Ltd., a privately held biopharmaceutical company, today announced the closing of a $15 million Series B preferred stock financing. New investor Forbion Capital Partners joined existing investors New Science Ventures and Third Point Ventures to complete the round. Akarna will use the funds to accelerate the development of its lead FXR agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH), a progressive form of fatty-liver disease for which there are no approved therapies. Source: Biospace 16/2/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).